<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction The SOCRATES-REDUCED Randomized Trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-11-08">November 8, 2015.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Mihai</forename><surname>Gheorghiade</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stephen</forename><forename type="middle">J</forename><surname>Greene</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH, MBA</roleName><forename type="first">Javed</forename><surname>Butler</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gerasimos</forename><surname>Filippatos</surname></persName>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><forename type="first">Carolyn</forename><forename type="middle">S P</forename><surname>Lam</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Aldo</forename><forename type="middle">P</forename><surname>Maggioni</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Piotr</forename><surname>Ponikowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Sanjiv</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">J</forename><surname>Shah</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Scott</forename><forename type="middle">D</forename><surname>Solomon</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Elisabeth</forename><surname>Kraigher-Krainer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eliana</forename><forename type="middle">T</forename><surname>Samano</surname></persName>
						</author>
						<author>
							<persName><roleName>DiplStat</roleName><forename type="first">Katharina</forename><surname>Müller</surname></persName>
						</author>
						<author>
							<persName><roleName>MD;</roleName><forename type="first">Lothar</forename><surname>Roessig</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Burkert</forename><surname>Pieske</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pieske</forename><surname>Kraigher- Krainer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">São</forename><surname>Bayer</surname></persName>
						</author>
						<author>
							<persName><roleName>Brazil (Samano</roleName><forename type="first">Bayer</forename><surname>Paulo</surname></persName>
						</author>
						<author>
							<persName><roleName>Wuppertal, Germany (Müller,</roleName><surname>Pharma</surname></persName>
						</author>
						<author>
							<persName><roleName>Greene, Shah, Samano.</roleName><surname>Gheorghiade</surname></persName>
						</author>
						<author>
							<persName><roleName>Filippatos, Lam, Maggioni, Ponikowski, Shah, Solomon, Samano, Müller, Roessig</roleName><forename type="first">Pieske</forename><surname>Butler</surname></persName>
						</author>
						<author>
							<persName><roleName>Greene, Butler, Filippatos, Lam, Maggioni, Ponikowski, Shah, Kraigher-Krainer, Samano, Müller, Roessig</roleName><forename type="first">Pieske</forename><surname>Gheorghiade</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lukas</forename><surname>Ameri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Charlotte</forename><surname>Buchheim</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Apollonia</forename><surname>Daburger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Ebner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Veronika</forename><surname>Eder</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Gregor</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><forename type="middle">Carmen</forename><surname>Gunacker</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Uta</forename><surname>Hoppe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Charlotte</forename><forename type="middle">Anna</forename><surname>Huber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gustav</forename><surname>Huber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dirk</forename><surname>Von Lewinski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Regina</forename><surname>Mascherbauer-Steringer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Deddo</forename><surname>Mörtl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Nemec</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Pfnib</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rita</forename><surname>Riedlbauer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Stefenelli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Sturmberger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicolas</forename><surname>Verheyen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maximilian</forename><surname>Winhard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wim</forename><surname>Anne</surname></persName>
						</author>
						<author>
							<persName><forename type="first">An-Kristin</forename><surname>Ascoop</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Philip</forename><surname>Baetsle</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Aydin</forename><surname>Basoglu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Oana</forename><surname>Bodea</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Borin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Cambier</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Coussement</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Philippe</forename><surname>Debonnaire</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michel</forename><surname>De Ceuninck</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><surname>Delforge</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Dëndooven</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Khaled</forename><surname>Draoui</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Karl</forename><surname>Dujardin</surname></persName>
						</author>
						<author>
							<persName><roleName>Michèle</roleName><forename type="first">Mattias</forename><surname>Duytschaever</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kamga</forename><surname>Dzukou</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frauke</forename><surname>Gorre</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Hausman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kurt</forename><surname>Hermans</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jean-Marc</forename><surname>Joris</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ruud</forename><surname>Koevoets</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jean</forename><surname>Leroy</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rachid</forename><surname>Maamar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Marchal</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Marechal</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Luc</forename><surname>Missault</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Luc</forename><surname>Muyldermans</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Nimmegeers</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anne- Catherine</forename><surname>Pouleur</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Max</forename><surname>Romagnoli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chris</forename><surname>Scheurwegs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Francis</forename><surname>Stammen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Harry</forename><surname>Striekwold</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rene</forename><surname>Tavernier</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Tombeux</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Louise</forename><surname>Tsessue</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Katarina</forename><surname>Van Beeumen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laurent</forename><forename type="middle">Vande</forename><surname>Kerckhove</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><surname>Vandekerckhove</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yves</forename><surname>Vandekerckhove</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Vanderdonckt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hugues</forename><surname>Verloove</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Geert</forename><surname>Vervoort</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Katia</forename><surname>Aleksieva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nikolay</forename><surname>Dimitrov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Neli</forename><surname>Georgieva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Zhozafina</forename><surname>Georgieva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mladen</forename><surname>Grigorov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Asen</forename><surname>Gudev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ivan</forename><surname>Kamburov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><surname>Kinova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Emil</forename><surname>Kolev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ivanka</forename><surname>Kulevska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tonka</forename><surname>Kurteva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bojidar</forename><surname>Krastev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Veselina</forename><surname>Mateeva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Milen</forename><surname>Minchev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Velentina</forename><surname>Mincheva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Petar</forename><surname>Petrov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatyana</forename><surname>Petrusheva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nikolay</forename><surname>Poroiliev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chavdar</forename><surname>Shalganov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Desislava</forename><surname>Smoleva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Natalia</forename><surname>Spasova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vasil</forename><surname>Stoyanovski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Veska</forename><surname>Tsanova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Toni</forename><surname>Velikov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Katerina</forename><surname>Vitlianova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Benoit</forename><surname>Coutu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sebastien</forename><surname>Bergeron</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Serge</forename><surname>Lepage</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Liszkowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gordon</forename><surname>Moe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Savard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Czech</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Belohlavek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Josef</forename><surname>Bis</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ondrej</forename><surname>Cermak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pavel</forename><surname>Cervinka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Dostalova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jaroslav</forename><surname>Dusek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lumir</forename><surname>Francek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marketa</forename><surname>Hegarova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomas</forename><surname>Hnatek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jiri</forename><surname>Knot</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomas</forename><surname>Kolouch</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ales</forename><surname>Kral</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eva</forename><surname>Krcova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Petr</forename><surname>Kuchynka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Macha</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vojtech</forename><surname>Melenovsky</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ivana</forename><surname>Marusincova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pavla</forename><surname>Nadenickova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Adrian</forename><surname>Reichenbach</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jana</forename><surname>Rudolecka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Radovan</forename><surname>Stancik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jiri</forename><surname>Teply</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pavel</forename><surname>Trestik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Renata</forename><surname>Valentikova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Zdenek</forename><surname>Vavera</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Vojacek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jevgenija</forename><surname>Vymetalova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Niels</forename><surname>Bruun</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Fog</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gunnar</forename><surname>Gislason</surname></persName>
						</author>
						<author>
							<persName><roleName>Bent</roleName><forename type="first">Søren</forename><surname>Mellemkjaer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Roni</forename><surname>Nielsen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Nielsen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kirsten</forename><surname>Nielsen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Refsgaard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Søgaard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Sørensen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hanne</forename><surname>Sortsøe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fabrice</forename><surname>Bauer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bastien</forename><surname>Glinel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pascal</forename><surname>De Groote</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Albert-Alain</forename><surname>Hagege</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nathan</forename><surname>Mewton</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yannick</forename><surname>Neuder</surname></persName>
						</author>
						<author>
							<persName><forename type="first">François</forename><surname>Picard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Johann</forename><surname>Bauersachs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Beug</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Böhm</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Felix</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cornelia</forename><surname>Finger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jürgen</forename><surname>Kilian</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ingrid</forename><surname>Kindermann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Harald</forename><surname>Lapp</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Niels</forename><surname>Menck</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kai</forename><surname>Müllerleile</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Riad</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Rosenkranz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Schäfer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Heribert</forename><surname>Schunkert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carolin</forename><surname>Sonne</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Reinhard</forename><surname>Stöhring</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joerg</forename><surname>Stypmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Viethen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><surname>Waltenberger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dirk</forename><surname>Westermann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernhard</forename><forename type="middle">R</forename><surname>Winkelmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sophia</forename><surname>Arapi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Kirschner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valery</forename><surname>Meledin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ebrahim</forename><surname>Noori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Imre</forename><surname>Varju</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mouin</forename><surname>Aboud</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Offer</forename><surname>Amir</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lev</forename><surname>Bloch</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Olga</forename><surname>Broudner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Natalie</forename><surname>Bogomolny</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Adi</forename><surname>Butnaru</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shemy</forename><surname>Carasso</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ehud</forename><surname>Chorin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dmitry</forename><surname>Dratva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatiana</forename><surname>Drogenikov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Irina</forename><surname>Fugenfirov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ben</forename><surname>Tuvia</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Diab</forename><surname>Gal</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sorel</forename><surname>Ghanim</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jihad</forename><surname>Goland</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tal</forename><surname>Hamuda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ofer</forename><surname>Hasin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Evgeny</forename><surname>Havakuk</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mohamed</forename><surname>Hazanov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rami</forename><forename type="middle">B</forename><surname>Jabaren</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eran</forename><surname>Jubeh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Amos</forename><surname>Kalmanovich</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Moayad</forename><surname>Katz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><forename type="middle">W</forename><surname>Khatib</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fabio</forename><surname>Klutstein</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jacek</forename><surname>Kusniec</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Israel</forename><surname>Linde</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Simcha</forename><forename type="middle">R</forename><surname>Mats</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gil</forename><surname>Meisel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mady</forename><surname>Moravsky</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Moriel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Menachem</forename><surname>Murninkas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ali</forename><surname>Nahir</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><surname>Nassar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Roman</forename><surname>Neiman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tsafrir</forename><surname>Nevzorov</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jana</forename><forename type="middle">Yehezkel</forename><surname>Or</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michal</forename><forename type="middle">Laufer</forename><surname>Paskin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatiana</forename><surname>Perl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dahud</forename><surname>Plaev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Youri</forename><surname>Qarawani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Rabkin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">May-Tal</forename><surname>Rahkovich</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nabeeh</forename><surname>Rofe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Salman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Avraham</forename><surname>Shochat</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hillel</forename><forename type="middle">A</forename><surname>Shotan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ivetta</forename><surname>Steiner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoav</forename><surname>Sukholutsky</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dan</forename><surname>Turgeman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lubov</forename><surname>Tzivoni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alicia</forename><surname>Vassilenko</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Zvi</forename><surname>Vazan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tanya</forename><surname>Vered</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giora</forename><surname>Weitsman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Inna</forename><surname>Wiesz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Liaz</forename><surname>Yofik</surname></persName>
						</author>
						<author>
							<persName><surname>Zilberman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Piergiuseppe</forename><surname>Agostoni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alessandro</forename><surname>Barbarossa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ivano</forename><surname>Bonadei</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giovanna</forename><surname>Branzi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ambra</forename><surname>Bulgarelli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><surname>Campana</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alessandro</forename><surname>Capucci</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valentina</forename><surname>Carubelli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">Grazia</forename><surname>Castelli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><forename type="middle">Isotta</forename><surname>Castrini</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gaia</forename><surname>Cattadori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Cattaneo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Cefalù</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Francesca</forename><surname>Ciambellotti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Franco</forename><surname>Cosmi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicolò</forename><surname>Dasseni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giuseppe</forename><surname>De Angelis</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Luigi</forename><surname>Delfino</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vincenzo</forename><surname>Duino</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giovanni</forename><surname>Forni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mafalda</forename><surname>Alessia</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valentina</forename><surname>Giglio</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alessandra</forename><surname>Giuli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paola</forename><surname>Gualco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Federico</forename><surname>Guarise</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rosanna</forename><surname>Guerra</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valentina</forename><surname>Jemoli</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><forename type="middle">Mario</forename><surname>Lazzarini</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Lombardi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gabriella</forename><surname>Lupi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">Vittoria</forename><surname>Malfatto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Matassini</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Metra</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Giorgio</forename><surname>Mollica</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Morando</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gianfranco</forename><surname>Opasich</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Parati</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Filippo</forename><surname>Pavesi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Quinzani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Valentina</forename><surname>Raineri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Regazzoni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michele</forename><surname>Scelsi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Franco</forename><surname>Senni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eleftheria</forename><surname>Tettamanti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monica</forename><surname>Trichaki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Annalisa</forename><surname>Tinto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Clara</forename><surname>Turco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Enrico</forename><surname>Villa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Isao</forename><surname>Vizzardi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Toru</forename><surname>Aburatani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Madoka</forename><surname>Aizawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kentaro</forename><surname>Akashi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takahiko</forename><surname>Amenomori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomohiro</forename><surname>Aoyama</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kenji</forename><surname>Asahi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mai</forename><surname>Ayata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Akio</forename><surname>Azuma</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hiroyuki</forename><surname>Chikata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nobuyuki</forename><surname>Doi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuki</forename><surname>Enzan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinya</forename><surname>Fukui</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kanichi</forename><surname>Fujii</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hiroyuki</forename><surname>Fujimori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kensuke</forename><surname>Fujinaga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susumu</forename><surname>Fujioka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hirofumi</forename><surname>Fujino</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ko</forename><surname>Fukagawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yukihiro</forename><surname>Fukuda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masaya</forename><surname>Fukuda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinnosuke</forename><surname>Fukuda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shoichiro</forename><surname>Furudono</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshitaka</forename><surname>Furukawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jun</forename><surname>Furuyashiki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chiaki</forename><surname>Fuse</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daiki</forename><surname>Goten</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kenji</forename><surname>Gyotoku</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomoya</forename><surname>Harada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomoko</forename><surname>Harada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshikazu</forename><surname>Henmi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Namio</forename><surname>Hiasa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Norioki</forename><surname>Higa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hidekazu</forename><surname>Hirano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Motoaki</forename><surname>Hirao</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shunichiro</forename><surname>Hirasawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasunari</forename><surname>Hondo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinobu</forename><surname>Hoshiba</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Naoki</forename><surname>Hosokawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kohei</forename><surname>Iinuma</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takeshi</forename><surname>Iguchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yukinori</forename><surname>Ikeda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshihiro</forename><surname>Ikegami</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tsutomu</forename><surname>Ikeuchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kohei</forename><surname>Ima</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Keita</forename><surname>Inagawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Harukazu</forename><surname>Inanaga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daiki</forename><surname>Iseki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshihiro</forename><surname>Ito</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takamasa</forename><surname>Imamura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomoko</forename><surname>Iwasawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shuhei</forename><surname>Izumi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Norihito</forename><surname>Kaibara</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Izaya</forename><surname>Kageyama</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Naomi</forename><surname>Kamei</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Naoko</forename><surname>Kanamori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chieko</forename><surname>Katagiri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shingo</forename><surname>Kato</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuko</forename><surname>Kato</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hiroya</forename><surname>Kato</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yota</forename><surname>Kawai</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masaki</forename><surname>Kawamura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hidekuni</forename><surname>Kinoshita</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Koichi</forename><surname>Kirigaya</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Katsunori</forename><surname>Kishi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kunihiko</forename><surname>Kitano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hiroshi</forename><surname>Kiuchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Seichi</forename><surname>Kobayashi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masashi</forename><surname>Kobayashi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masaya</forename><surname>Koga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shigeru</forename><surname>Kurobe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuka</forename><surname>Kuroki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomohito</forename><surname>Kusakawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mamoru</forename><surname>Mabuchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michiro</forename><surname>Manita</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tami</forename><surname>Maruyama</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takuya</forename><surname>Mashidori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuko</forename><surname>Mayumi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazutoshi</forename><surname>Miki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Naoya</forename><surname>Minami</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takashi</forename><surname>Mitsuba</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hitoshi</forename><surname>Miwa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Junichi</forename><surname>Miyajima</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuji</forename><surname>Miyamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yutaka</forename><surname>Miyazaki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yukihiko</forename><surname>Mizumasa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ayako</forename><surname>Momiyama</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kyoko</forename><surname>Monji</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasuhiro</forename><surname>Mori</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susumu</forename><surname>Morikami</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takahiro</forename><surname>Morosawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hideo</forename><surname>Muroya</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshiki</forename><surname>Nagai</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatsuya</forename><surname>Nagata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoichiro</forename><surname>Nakachi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ryuichi</forename><surname>Nakagawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masatsugu</forename><surname>Nakaike</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hiroshi</forename><surname>Nakano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mayui</forename><surname>Nakashima</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marohito</forename><surname>Nakazawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hisato</forename><surname>Nakata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuhiro</forename><surname>Nako</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Satoru</forename><surname>Nitta</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinpei</forename><surname>Niwa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasumasa</forename><surname>Nogi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuichi</forename><surname>Nouno</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatsuya</forename><surname>Numata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshihiro</forename><surname>Nunohiro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Riyo</forename><surname>Noji</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shogo</forename><surname>Ogura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ayumi</forename><surname>Oishi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Katsunori</forename><surname>Okada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fumio</forename><surname>Okajima</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mitsunori</forename><surname>Okamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sho</forename><surname>Okamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takanobu</forename><surname>Okamura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wataru</forename><surname>Okumura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Haruhiko</forename><surname>Omi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tetsuari</forename><surname>Onaka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jun</forename><surname>Onishi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuki</forename><surname>Osada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ryuji</forename><surname>Oshida</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Koji</forename><surname>Otani</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takahiro</forename><surname>Otsuka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Satoru</forename><surname>Saeki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Munehisa</forename><surname>Sakagami</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinichiro</forename><surname>Sakamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takuo</forename><surname>Sakota</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Koji</forename><surname>Sakura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takahiro</forename><surname>Sato</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomokazu</forename><surname>Sawada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Akira</forename><surname>Sawada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kuniyuki</forename><surname>Shimane</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuyoshi</forename><surname>Shirasawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatsuya</forename><surname>Suenari</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Toru</forename><surname>Sugihara</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinichiro</forename><surname>Sugiura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuhiko</forename><surname>Sunamura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takefumi</forename><surname>Tabata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Midori</forename><surname>Takahashi</surname></persName>
						</author>
						<author>
							<persName><surname>Takakura</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Satoshi</forename><surname>Takeshita</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuki</forename><surname>Tanaka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Toshie</forename><surname>Tanaka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasuyo</forename><surname>Taniguchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kojiro</forename><surname>Tanimoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Naho</forename><surname>Terada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jin</forename><surname>Teranishi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takayoshi</forename><surname>Toba</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yohei</forename><surname>Tobetto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomoyuki</forename><surname>Tobushi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hideki</forename><surname>Tokuhisa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tetsuya</forename><surname>Tomariguchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hideko</forename><surname>Tomimoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takumi</forename><surname>Tozawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasue</forename><surname>Tsukishiro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takaki</forename><surname>Tsutsumi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatsuro</forename><surname>Uchida</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mio</forename><surname>Uchida</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuzo</forename><surname>Uchida</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomoki</forename><surname>Uchikawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hironori</forename><surname>Ueda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tokuhisa</forename><surname>Uejima</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoji</forename><surname>Urabe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kazuo</forename><surname>Usuda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomohiko</forename><surname>Watanabe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuichiro</forename><surname>Watari</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masahiro</forename><surname>Yagi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Akira</forename><surname>Yamada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nao</forename><surname>Yamada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinichiro</forename><surname>Yamada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takahiro</forename><surname>Yamada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masahiro</forename><surname>Yamagami</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Masato</forename><surname>Yamaguchi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fumi</forename><surname>Yamamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hirofumi</forename><surname>Yamamoto</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ryo</forename><surname>Yamazato</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yoshinori</forename><surname>Yasaka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bun</forename><surname>Yashiro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatsuo</forename><surname>Yasuoka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kiminobu</forename><surname>Yokoi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yasuhiro</forename><surname>Yokoyama</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kohei</forename><surname>Yoneda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kenichiro</forename><surname>Yuba</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><forename type="middle">A</forename><surname>Badings</surname></persName>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Breedveld</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>De Nooijer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">W</forename><forename type="middle">E M</forename><surname>Kok</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><forename type="middle">J A</forename><surname>Lok</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fabrice</forename><surname>Martens</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Remco</forename><surname>Nijmeijer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Tjeerdsma</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Perik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Luc</forename><surname>Theunissen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marieke</forename><surname>Torn</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ype</forename><surname>Tuininga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maciej</forename><surname>Banasiak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Slawomir</forename><surname>Bobon</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tomasz</forename><surname>Ciurus</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monika</forename><surname>Chudzicka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Urszula</forename><surname>Czubek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jaroslaw</forename><surname>Drozdz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Engel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrzej</forename><surname>Gackowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Gil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Karolina</forename><surname>Golinska-Grzybala</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Grajek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Jakubowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marcin</forename><surname>Kasprzyk</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Miroslaw</forename><surname>Kastelik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lukasz</forename><surname>Kicinski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Aneta</forename><surname>Klotzka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Krekora</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Waldemar</forename><surname>Krysiak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Malgorzata</forename><surname>Lange-Szczesiak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Magdalena</forename><surname>Misztal-Teodorczyk</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Beata</forename><surname>Moczulska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Renata</forename><surname>Mroziak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wlodzimierz</forename><surname>Musial</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jadwiga</forename><surname>Nessler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alicja</forename><surname>Nowak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Zofia</forename><surname>Oko-Sarnowska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Agnieszka</forename><surname>Pawlak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Grzegorz</forename><surname>Piotrowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Przybylska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pawel</forename><surname>Rehan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Rola</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edyta</forename><surname>Skorek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marta</forename><surname>Stepien</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ewa</forename><surname>Straburzynska-Migaj</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Krzysztof</forename><surname>Szymczak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Beata</forename><surname>Tomaszewska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Agnieszka</forename><surname>Tycinska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marta</forename><surname>Wegrzynowska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tadeusz</forename><surname>Zechowicz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Miguel</forename><surname>Cainzos Achiriga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sergio</forename><forename type="middle">García</forename><surname>Blas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Almenar</forename><surname>Luís</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Manuel</forename><forename type="middle">Gómez</forename><surname>Bonet</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sonia</forename><forename type="middle">Ruíz</forename><surname>Bueno</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Amparo</forename><surname>Bustillo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fernando</forename><forename type="middle">Cereto</forename><surname>Carrasco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Josep</forename><forename type="middle">Comín</forename><surname>Castro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jordi</forename><surname>Colet</surname></persName>
						</author>
						<author>
							<persName><surname>Bruguera Cortada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martínez</forename><surname>Luís</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ignasi</forename><surname>Dolz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">José</forename><surname>Durán</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><forename type="middle">Enjuanes</forename><surname>González</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ignacio</forename><forename type="middle">Sánchez</forename><surname>Grau</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Núria</forename><surname>Lázaro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Clara</forename><forename type="middle">Bonanad</forename><surname>Farré López</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Lozano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicolás</forename><surname>Couto Mallón</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marta</forename><surname>Manito</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marcos</forename><surname>Cobo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joel</forename><forename type="middle">Salazar</forename><surname>Mendiguchía</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Herminio</forename><surname>Morillas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Julio</forename><surname>Núñez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Enrique</forename><surname>Santas Olmeda</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Diego</forename><surname>Plaza</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marcelo</forename><surname>Rizzo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Josep</forename><surname>Roca</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Iris</forename><surname>Rodríguez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ruperto</forename><surname>Carlos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Olivero</forename><surname>Soldevilla</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ernesto</forename><surname>Valero</surname></persName>
						</author>
						<author>
							<persName><forename type="first">José</forename><forename type="middle">Antonio</forename><surname>Vázquez De Prada</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Francisco</forename><surname>González Vílchez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sweden</forename><forename type="middle">:</forename><surname>Per</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Urban</forename><surname>Alehagen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monthir</forename><surname>Alfetlawi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Karin</forename><surname>Arinell</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stella</forename><surname>Cizinsky</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rolanda</forename><surname>Daher-Knutsen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Dahlström</surname></persName>
						</author>
						<author>
							<persName><roleName>Edit Floderer</roleName><forename type="first">Maja</forename><surname>Eriksson-Östman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ole</forename><surname>Hansen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ola</forename><surname>Hallén</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Hedman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laila</forename><surname>Hübbert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dimitrios</forename><surname>Kostakiotis</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Johan</forename><surname>Lugnegård</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dora</forename><surname>Norring</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Olson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Emil</forename><surname>Pantev</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stagmo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Barna</forename><surname>Szabo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gordana</forename><surname>Tasevska-Dinevska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fredrik</forename><surname>Utter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Wodlin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monya</forename><surname>Bondio</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carmela</forename><surname>Crljenica</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Enseleit</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Estlinbaum</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Flammer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michelle</forename><surname>Frank</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><surname>Gutmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><surname>Kniencke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Kreuzer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gregor</forename><surname>Leibundgut</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sandrine</forename><surname>Meyer-Monard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tiziano</forename><surname>Moccetti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Montipanzeri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Rickenbacher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mariagrazia</forename><surname>Rossi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Ruschitzka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Isabella</forename><surname>Sudano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wan-Khey</forename><surname>Chan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yi-Yao</forename><surname>Chang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chern-En</forename><surname>Chiang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fu-Tien</forename><surname>Chiang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yu-Wei</forename><surname>Chiu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wen-Po</forename><surname>Chuang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jung-Cheng</forename><surname>Hsu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shan-Hui</forename><surname>Huang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Juey-Jen</forename><surname>Hwang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jyn-Ming</forename><surname>Juang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shin-Rong</forename><surname>Ke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wen-Ter</forename><surname>Lai</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pen-Chih</forename><surname>Liao</surname></persName>
						</author>
						<author>
							<persName><roleName>Heng</roleName><forename type="first">Chun-Chung</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hsu</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jiunn-Lee</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lian-Yu</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lung-Chun</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shing-Jong</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yen-Hung</forename><surname>Lin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cheng-Wei</forename><surname>Liu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yuan-Hung</forename><surname>Liu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tse-Min</forename><surname>Lu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ju-Pin</forename><surname>Pan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shih-Hsien</forename><surname>Sung</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chia-Ti</forename><surname>Tsai</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chung-Ming</forename><surname>Tu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kang-Ling</forename><surname>Wang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tzung-Dau</forename><surname>Wang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cho-Kai</forename><surname>Wu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yen-Wen</forename><surname>Wu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wen-Chung</forename><surname>Yu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Justin</forename><surname>Cooke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mohamed</forename><surname>Farag</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Diana</forename><surname>Gorog</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Clare</forename><surname>Hawley</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Osita</forename><surname>Okafor</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anthony</forename><surname>Alfieri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Douglas</forename><surname>Chapman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Veronica</forename><surname>Franco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Gianfagna</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jalal</forename><surname>Ghali</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Steven</forename><surname>Goldsmith</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Garrie</forename><surname>Haas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Lanfear</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joshua</forename><surname>Larned</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Lenihan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Long</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Markham</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Mcgrew</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vinay</forename><surname>Mehta</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Pham</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sajan</forename><surname>Rao</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Smart</surname></persName>
						</author>
						<author>
							<persName><forename type="first">James</forename><surname>Talano</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Filippatos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carolyn</forename><surname>Ponikowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Aldo</forename><forename type="middle">P</forename><surname>Lam</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sanjiv</forename><forename type="middle">J</forename><surname>Maggioni</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Scott</forename><forename type="middle">D</forename><surname>Shah</surname></persName>
						</author>
						<author>
							<persName><surname>Solomon</surname></persName>
						</author>
						<author>
							<persName><forename type="first">John</forename><forename type="middle">J V</forename><surname>Mcmurray</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Granger</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wilhelm</forename><forename type="middle">Haverkamp</forename><surname>Clinical</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Northwestern University Feinberg School of Medicine</orgName>
								<address>
									<addrLine>201 E Huron St, Galter 3-150</addrLine>
									<postCode>60611</postCode>
									<settlement>Chicago</settlement>
									<region>IL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Center for Cardiovascular Innovation</orgName>
								<orgName type="department" key="dep2">Illinois (Gheorghiade)</orgName>
								<orgName type="institution">Northwestern University Feinberg School of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Division of Cardiology</orgName>
								<orgName type="institution">Duke University Medical Center</orgName>
								<address>
									<settlement>Durham</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Cardiology</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="laboratory">Heart Failure Unit</orgName>
								<orgName type="institution" key="instit1">North Carolina (Greene)</orgName>
								<orgName type="institution" key="instit2">Stony Brook University</orgName>
								<address>
									<settlement>Stony Brook, New York (Butler)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Athens University Hospital Attikon</orgName>
								<orgName type="institution" key="instit2">National and Kapodistrian University of Athens</orgName>
								<address>
									<settlement>Athens</settlement>
									<country>Greece (Filippatos</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution" key="instit1">National Heart Centre Singapore and Duke</orgName>
								<orgName type="institution" key="instit2">National University of Singapore</orgName>
								<address>
									<settlement>Singapore (Lam)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Heart Diseases</orgName>
								<orgName type="institution">Associazione Nazionale Medici Cardiologi Ospedalieri Research Center</orgName>
								<address>
									<settlement>Florence</settlement>
									<country>Italy (Maggioni</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Division of Cardiology</orgName>
								<orgName type="institution">Medical University, Military Hospital</orgName>
								<address>
									<settlement>Wroclaw</settlement>
									<country>Poland (Ponikowski</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution">Northwestern University Feinberg School of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Brigham and Women&apos;s Hospital</orgName>
								<orgName type="institution">Illinois (Shah)</orgName>
								<address>
									<addrLine>Cardiovascular Division</addrLine>
									<settlement>Boston</settlement>
									<region>Massachusetts (Solomon)</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine and Cardiology</orgName>
								<orgName type="institution">Charité University Medicine Berlin-Campus Virchow Klinikum</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Roessig)</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine and Cardiology</orgName>
								<orgName type="institution">German Heart Center Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany (Pieske</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Despoina Balta</orgName>
								<address>
									<addrLine>Apostolos Karavidas, Anastasia Perpinia</addrLine>
									<settlement>Stylianos Fotakis, Sotirios Patsilinakos, George Tsitsinakis, Eleftherios Vidalakis</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="laboratory">Vericiguat and Worsening Chronic Heart Failure Original Investigation Research</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="institution" key="instit1">Ruben Uijlings</orgName>
								<orgName type="institution" key="instit2">Aize van der Sluis</orgName>
								<address>
									<settlement>Jan van Wijngaarden</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="institution">Cristina Tita</orgName>
								<address>
									<addrLine>Lynne Wagoner</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="institution">Michael Zile</orgName>
								<address>
									<country>Dianne Zwicke</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction The SOCRATES-REDUCED Randomized Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-11-08">November 8, 2015.</date>
						</imprint>
					</monogr>
					<idno type="MD5">6794508ADA83BD9E5A6D1300CEAD34C6</idno>
					<idno type="DOI">10.1001/jama.2015.15734</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Gheorghiade</term>
					<term>Greene</term>
					<term>Butler</term>
					<term>Roessig</term>
					<term>Pieske Gheorghiade</term>
					<term>Greene</term>
					<term>Butler</term>
					<term>Maggioni</term>
					<term>Ponikowski</term>
					<term>Roessig</term>
					<term>Pieske Mihai Gheorghiade (co-chair)</term>
					<term>Burkert Pieske (co-chair)</term>
					<term>Javed Butler</term>
					<term>Gerasimos Gerasimos Filippatos (chair)</term>
					<term>Aldo P. Maggioni</term>
					<term>Piotr Ponikowski</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IMPORTANCE</head><p><s>Worsening chronic heart failure (HF) is a major public health problem.</s></p><p><s>OBJECTIVE To determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic HF and reduced left ventricular ejection fraction (LVEF).</s></p><p><s>DESIGN, SETTING, AND PARTICIPANTS Dose-finding phase 2 study that randomized 456 patients across Europe, North America, and Asia between November 2013 and January 2015, with follow-up ending June 2015.</s><s>Patients were clinically stable with LVEF less than 45% within 4 weeks of a worsening chronic HF event, defined as worsening signs and symptoms of congestion and elevated natriuretic peptide level requiring hospitalization or outpatient intravenous diuretic.</s><s>INTERVENTIONS Placebo (n = 92) or 1 of 4 daily target doses of oral vericiguat (1.25 mg [n = 91], 2.5 mg [n = 91], 5 mg [n = 91], 10 mg [n = 91]) for 12 weeks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MAIN OUTCOMES AND MEASURES</head><p><s>The primary end point was change from baseline to week 12 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP).</s><s>The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>Overall, 351 patients (77.0%) completed treatment with the study drug with valid 12-week NT-proBNP levels and no major protocol deviation and were eligible for primary end point evaluation.</s><s>In primary analysis, change in log-transformed NT-proBNP levels from baseline to week 12 was not significantly different between the pooled vericiguat group (log-transformed: baseline, 7.969; 12 weeks, 7.567; difference, −0.402; geometric means: baseline, 2890 pg/mL; 12 weeks, 1932 pg/mL) and placebo (log-transformed: baseline, 8.283; 12 weeks, 8.002; difference, −0.280; geometric means: baseline, 3955 pg/mL; 12 weeks, 2988 pg/mL) (difference of means, −0.122; 90% CI, −0.32 to 0.07; ratio of geometric means, 0.885, 90% CI, 0.73-1.08;</s><s>P = .15).</s><s>The exploratory secondary analysis suggested a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level (P &lt; .02).</s><s>Rates of any adverse event were 77.2% and 71.4% among the placebo and 10-mg vericiguat groups, respectively.</s></p><p><s>CONCLUSIONS AND RELEVANCE Among patients with worsening chronic HF and reduced LVEF, compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerated.</s><s>Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>M</head><p><s>ore than 1 million hospitalizations for heart failure (HF) occur annually in the United States alone, and more than 80% of these hospitalized patients have worsening chronic HF. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> Despite an often rapid and substantial in-hospital improvement in HF signs and symptoms with standard therapy, approximately 25% of patients are rehospitalized within 30 days and 30% of patients may die within 1 year. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s>Patients with worsening chronic HF who are not hospitalized, but require outpatient intravenous diuretic administration, may carry a similarly poor prognosis. <ref type="bibr" target="#b4">5</ref></s><s>reclinical and clinical evidence supports augmentation of the nitric oxide-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway as a potential therapeutic target for worsening chronic HF.</s><s>]<ref type="bibr" target="#b9">[8]</ref><ref type="bibr" target="#b10">[9]</ref> In HF, increased inflammation and vascular dysfunction results in reduced nitric oxide bioavailability, with resultant decrease in downstream cGMP synthesis. <ref type="bibr" target="#b10">9</ref></s><s>This cGMP deficiency causes systemic, coronary, and renal microcirculatory dysfunction, which may lead to progressive myocardial damage and further inflammation. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b8">7,</ref><ref type="bibr" target="#b11">10</ref></s><s>Derangements in cGMP signaling have been correlated with worse clinical outcomes among patients with reduced left ventricular ejection fraction (LVEF). <ref type="bibr" target="#b5">6</ref></s><s>oluble guanylate cyclase stimulators offer a novel approach for addressing the relative cGMP deficit in worsening chronic HF.</s><s>These agents modulate sGC in a nitric oxide-independent manner, mimicking nitric oxide and restoring downstream cGMP signaling.</s><s>The recent availability of oral formulations of sGC stimulators affords the opportunity to test the hypothesis that enhancement of the cGMP pathway using an sGC stimulator will favorably influence the clinical course of worsening chronic HF.</s><s>The Soluble Guanylate Cyclase Stimulator in Heart Failure with Reduced Ejection Fraction Study (SOCRATES-REDUCED) was designed to evaluate the effect on natriuretic peptide trajectory and tolerability of 12 weeks of treatment with 4 doses of oral vericiguat (BAY1021189), a novel once-daily sGC stimulator, in clinically stable patients with worsening chronic HF and reduced LVEF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>SOCRATES-REDUCED was a multicenter, randomized, doubleblind, placebo-controlled, dose-finding trial that enrolled patients with worsening chronic HF after clinical stabilization.</s><s>The study design has been previously described, and the protocol and statistical analysis plan are online (see the trial protocol in Supplement 1 and statistical analysis plan in Supplement 2). <ref type="bibr" target="#b12">11</ref></s><s>Institutional review board or ethics committee approval was obtained at each study site.</s><s>All patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Patients</head><p><s>The full inclusion and exclusion criteria of the SOCRATES-REDUCED study can be found in the trial protocol in Supplement 1. <ref type="bibr" target="#b12">11</ref> Briefly, eligible patients had LVEF less than 45% and a recent episode of worsening chronic HF defined by 3 components: (1) worsening HF symptoms requiring either hospital-ization or outpatient administration of intravenous diuretics;</s></p><p><s>(2) signs of congestion (clinical or chest radiograph findings); and (3) elevated natriuretic peptide level (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥1000 pg/mL or B-type natriuretic peptide [BNP] ≥300 pg/mL if in sinus rhythm, or NT-proBNP ≥1600 pg/mL or BNP ≥500 pg/mL if in atrial fibrillation [BNP inclusion level criteria were different in Japan; see the eAppendix in Supplement 3]).</s><s>All patients had a history of chronic HF, defined as New York Heart Association class II through IV symptoms and treatment with guideline-directed medical HF therapy for 30 days or longer before hospitalization or intravenous diuretic administration without hospitalization.</s><s>Prior to randomization, patients were required to be clinically stable, defined as not having received intravenous vasodilator therapy for at least 24 hours and not having received intravenous diuretic therapy for at least 12 hours, and having systolic blood pressure 110 mm Hg or greater and less than 160 mm Hg, and heart rate 50/min or greater and less than 100/min.</s></p><p><s>Exclusion criteria included intravenous inotropes at any time between hospitalization and randomization; concurrent use of nitrates, phosphodiesterase type 5 inhibitors, or alternative sGC stimulators; acute coronary syndrome within 60 days prior to randomization; listing for cardiac transplant or anticipated placement of ventricular assist device; glomerular filtration rate less than 30 mL/min; and several specific HF etiologies, including hypertrophic cardiomyopathy, pericardial disease, infiltrative/inflammatory myocardial disease, and severe valvular disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design</head><p><s>Patients who met selection criteria were randomized 1:1:1:1:1 to 1 of 5 equally sized study groups (4 vericiguat groups, 1 placebo group) (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Patients were randomized in blocks with a block size of 10.</s><s>If patient screening began during hospitalization, randomization occurred within 4 weeks of clinical stabilization, either before or after discharge.</s><s>If screening began after hospital discharge, the randomization period extended up to 4 weeks after the index discharge.</s><s>When screening began after outpatient intravenous diuretic therapy, randomization was permitted for 4 weeks from time of diuretic administration.</s><s>Patient race/ethnicity was recorded and determined at the discretion of the investigator.</s></p><p><s>The 4 vericiguat treatment groups targeted a maximal dose of 1.25 mg, 2.5 mg, 5 mg, and 10 mg, administered orally once daily.</s><s>All active treatment groups except the 1.25-mg once-daily group started with 2.5 mg once daily of vericiguat at randomization (visit 1).</s><s>Study protocol specified up-titration (ie, dose doubling) or sham titration of dose at week 2 (visit 2) and week 4 (visit 3) after randomization.</s><s>Dose titration in all groups was predicated on safety assessments and systolic blood pressure criteria.</s><s>Planned total treatment duration was 12 weeks (visit 5), followed by a safety follow-up at 16 weeks after randomization.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study End Points</head><p><s>The primary end point of the study was change from baseline to week 12 in log-transformed NT-proBNP level.</s><s>All additional end points were exploratory or related to safety.</s><s>Echocardiographic end points included changes in LVEF, left ventricular</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>A sample size of 325 patients (65 patients per study group) was estimated to provide 80% power for the primary analysis with 1-sided α = 5%.</s><s>Assuming a 20% dropout rate, 410 was the target sample size for randomization.</s><s>This calculation was based on an earlier study of an sGC stimulator in patients with reduced LVEF and pulmonary hypertension and derived from an assumed  difference in treatment effect of −0.187 log (pg/mL) between the placebo and pooled treatment groups with a standard deviation of 0.52 log (pg/mL). <ref type="bibr" target="#b12">11,</ref><ref type="bibr" target="#b13">12</ref></s><s>The full analysis set for the present study included all patients randomized to treatment and was used to display baseline characteristics and exploratory efficacy assessments.</s><s>The safety analysis set included the full analysis set of all patients who received at least 1 dose of the study drug and was used to display safety data.</s><s>The per-protocol set included all patients randomized to treatment who were alive with valid measurement of NT-proBNP at baseline and week 12 and had no major protocol deviations.</s><s>The per-protocol set was used for primary efficacy analysis, with the rationale being that intention-to-treat analysis would require inclusion of patients without postbaseline NT-proBNP values and thus be less appropriate for a dosefinding study.</s><s>Nonetheless, several sensitivity analyses were performed including imputation by last observation carried forward, an analysis of observed cases that included patients with visit 5 NT-proBNP values and patients who dropped out due to adverse event or death, and multiple imputation analysis.</s></p><p><s>For the primary analysis of the primary end point, the 3 highest-dose vericiguat groups (2.5 mg, 5 mg, and 10 mg) were prespecified to be pooled and compared with placebo with a 2-sample t test at the 1-sided significance level α = 5%.</s><s>The 1.25-mg dose group was assumed to have no or minimal effect and hence was not included in the pool of presumed effective dose groups.</s><s>Secondary analyses of the primary end point were prespecified to investigate a dose-response relationship by linear regression model.</s><s>In addition, if the null hypothesis of the primary analysis was rejected, pairwise comparisons of the individual vericiguat groups with placebo were planned in a hierarchical manner with a 2-sample t test at the 1-sided significance level α = 5%.</s><s>If the primary analysis showed no statistical significance, comparisons of individual dose groups with placebo were to be deemed descriptive only.</s><s>Only the primary and secondary analyses of NT-proBNP change from baseline to 12 weeks were prespecified in the hierarchical testing procedure and thus were α-adjusted (secondary analyses only α-adjusted if primary analysis statistically significant).</s><s>All other analyses and end points were only exploratory, and hence P values are only descriptive and do not reflect statistical significance.</s><s>SAS version 9.2 was used for all analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Of the 632 patients screened, 456 patients were randomized (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>The mean (SD) time from clinical stabilization to randomization was 14.4 (9.8) days.</s><s>Patients were randomized from 144 sites across Europe, North America, and Asia between November 2013 and January 2015.</s><s>The follow-up period ended in June 2015.</s><s>Overall, 351 patients (77.0%) completed treatment with study drug with valid 12-week NT-proBNP levels and no major protocol deviation and were included in the perprotocol set for evaluation of the primary end point.</s><s>There were 6 patients (1.3%) with unknown vital status at completion of safety follow-up.</s></p><p><s>The treatment groups were generally well balanced with respect to baseline characteristics, with exception of higher me-dian baseline NT-proBNP level among those randomized to receive placebo and 1.25-mg vericiguat (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Overall, 77.9% of patients fulfilled worsening chronic HF criteria by being hospitalized, and 22.1% met criteria by requiring outpatient intravenous diuretic use.</s><s>Mean age of the cohort was 68 years, and the majority of patients were men and white.</s><s>Mean LVEF was 29.6%, and mean blood pressure was 126/75 mm Hg.</s><s>Median baseline NT-proBNP level was 3076 pg/mL, and mean estimated glomerular filtration rate was 58 mL/min/1.73</s><s>m 2 .</s><s>At randomization, patients were receiving diuretics (94%), angiotensin-converting enzyme (ACE) inhibitors (61%), angiotensin II receptor blockers (23%), β-blockers (90%), and mineralocorticoid receptor antagonists (62%).</s><s>The actual study medication dosing achieved per the protocol dose titration schedules is displayed in eTable 1 in Supplement 3. Of those patients randomized to receive the highest vericiguat dose and receiving study treatment on and after 8 weeks of follow-up, 71.8% reached the 10-mg daily target dose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary End Point</head><p><s>Analyses of the primary end point are displayed in Figure <ref type="figure" target="#fig_1">2</ref> and Table <ref type="table" target="#tab_2">2</ref>.</s><s>The primary end point, change in log-transformed NT-proBNP level from baseline to 12 weeks, was not significantly different in the pooled vericiguat treatment group (log-transformed values: baseline, 7.969; 12 weeks, 7.567; difference, −0.402; geometric means: baseline, 2890 pg/mL; 12 weeks, 1932 pg/mL) compared with the placebo group (log-transformed values: baseline, 8.283; 12 weeks, 8.002; difference, −0.280; geometric means: baseline, 3955 pg/mL; 12 weeks, 2988 pg/mL) (difference of means, −0.122; 90% CI, −0.32 to 0.07; ratio of geometric means on original scale, 0.885; 90% CI, 0.73-1.08;</s><s>P = .15).</s><s>Exploratory secondary analyses of the primary end point using linear regression modeling suggested a dose-response relationship (P &lt; .02),</s><s>with higher vericiguat doses associated with greater reduction in NT-proBNP levels.</s><s>Several sensitivity analyses, including imputation by last observation carried forward, an analysis of observed cases that included patients with visit 5 NT-proBNP values and patients dropping out due to adverse event or death, and multiple imputation analysis, did not meaningfully alter results.</s><s>Results of sensitivity analyses for the primary and secondary analyses of the primary end point are displayed in eTable 3, eTable 4, and eTable 5 in Supplement 3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory End Points</head><p><s>Pairwise exploratory analyses of individual vericiguat groups found differences in the primary end point between the 10-mg vericiguat group (log-transformed values: baseline,  Additional select exploratory clinical and echocardiographic end points are displayed in Table <ref type="table" target="#tab_1">3</ref> and Table <ref type="table" target="#tab_3">4</ref>.</s></p><p><s>All-cause death as 12 weeks occurred at a rate of 3.3% among patients taking placebo and 2.2% to 4.4% among patients randomized to receive vericiguat.</s><s>The rate of HF hospitalization at 12 weeks was 9.9% in the 10-mg and 5-mg vericiguat groups, 17.6% in the 2.5-mg and 1.25-mg groups, and 17.4% in the placebo group.</s><s>The rate of the composite of cardiovascular death or HF hospitalization was 11% in the 10-mg vericiguat group, 12.1% in the 5-mg group, 19.8% in the 2.5-mg group, 18.7% in the 1.25-mg group, and 19.6% in the placebo group (Figure <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Outcomes</head><p><s>Safety outcomes were evaluated in all patients who received at least 1 dose of the study drug (455 patients, safety analysis set).</s><s>Data for adverse events (AEs), serious AEs (SAEs), and study discontinuations secondary to AEs are displayed in Table <ref type="table" target="#tab_5">5</ref>.</s><s>Rates of any AE were similar across study groups: 77.2% among patients taking placebo and as high as 78.9% among the vericiguat groups (2.5-mg group).</s><s>Rates of SAE were highest among placebo patients at 39.1%.</s><s>Rates of treatment-emergent acute kidney injury (placebo: 3.3%; vericiguat groups: 1.1%-5.5%)</s><s>and study drug discontinuation due to SAEs (placebo: 5.4%; vericiguat groups: 2.2%-7.7%)</s><s>were similar between treatment groups.</s><s>Treatment-emergent syncope was most frequent in the 10-mg vericiguat group (4 patients, 4.4%; in 3/4 patients, events occurred during the first 2 weeks after randomization, ie, when taking the 2.5-mg dose).</s><s>Treatment-emergent hypotension was most common in the 10-mg vericiguat group (14 patients, 15.4%) and was next most frequent in the 2.5-mg vericiguat group (6 patients, 6.7%).</s><s>Among the 14 patients with treatmentemergent hypotension in the 10-mg vericiguat group, 8 patients experienced hypotension between weeks 0 and 2, when the maximal vericiguat dose per the study titration schedule was 2.5 mg once daily.</s><s>Two patients experienced hypotension between weeks 2 and 4, when the maximal vericiguat dose was 5 mg once daily.</s><s>The cumulative proportion of patients with treatment-emergent hypotension during the first 2 weeks in the three 2.5-mg startingdose groups was 4.4%, compared with 3.3% in the placebo group.</s><s>Two patients in the trial discontinued the study drug due to hypotension (1 in the placebo group; 1 in the 5-mg vericiguat group).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The SOCRATES-REDUCED trial was designed to evaluate the tolerability and optimal dose of 4 regimens of vericiguat in stabilized patients with worsening chronic HF and reduced LVEF.</s><s>The primary analysis of the primary end point was not met, as pooled analysis of the 3 higher-dose vericiguat groups found no significant difference in 12-week NT-proBNP reduction compared with placebo.</s><s>Prespecified secondary analyses demonstrated a dose-response relationship between increasing vericiguat dose and NT-proBNP reduction.</s><s>Overall, vericiguat appeared well tolerated without an excess in AEs or SAEs compared with placebo.</s><s>Further prospective testing in a phase 3 trial is needed to definitively determine the effect of vericiguat on clinical outcomes in this patient population.</s></p><p><s>The nitric oxide-sGC-cGMP pathway represents a longestablished therapeutic target in HF with reduced LVEF, most notably with use of combination isosorbide dinitrate and hydralazine therapy in African American patients. <ref type="bibr" target="#b14">13</ref></s><s>More recently, targeting the particulate guanylate cyclase-cGMP pathway via neprilysin inhibition and augmentation of the natriuretic peptide system demonstrated clinical benefits. <ref type="bibr" target="#b16">14</ref></s><s>However, additional attempts at cGMP enhancement in HF with reduced LVEF have been challenging, as treatment with exogenous organic nitrates is limited by tolerance and impaired bioactivation. <ref type="bibr" target="#b19">15</ref></s><s>Moreover, oxidative stress decreases the sensitivity of sGC to nitric oxide, which  may impair downstream cGMP production even if nitric oxide levels are sufficient. <ref type="bibr" target="#b5">6</ref></s><s>Direct sGC modulators have the advantage of stimulating sGC in a nitric oxide-independent manner, circumventing problems with reduced upstream nitric oxide bioavailability and diminished endogenous activity of sGC.</s></p><p><s>Although the primary analysis of the primary end point of this trial was not met, there are several notable findings.</s><s>The first is that all doses of vericiguat appeared well tolerated compared with placebo.</s><s>Patients receiving placebo and those in the 2.5-mg vericiguat group had higher rates of any SAE and any AE compared with other vericiguat groups.</s><s>While this study was not powered for clinical events, rates of mortality and HF hospitalization were generally numerically lower among patients receiving vericiguat, particularly among those randomized to the 2 highest-dose vericiguat groups.</s><s>Specifically, the rate of HF hospitalization in these 2 highest-dose vericiguat groups was 9.9% compared with 17.4% to 17.6% in the placebo and lower-dose vericiguat groups.</s><s>Although investigator-reported episodes of treatment-emergent hypotension and syncope were more frequent among patients in the highest-dose vericiguat group, these events did not prompt excess study drug discontinuation, and there were no significant differences in 12-week follow-up blood pressure and heart rate measurements among patients randomized to receive 10-mg vericiguat or placebo.</s><s>Moreover, excess hypotensive events in the 10-mg vericiguat group were mostly early events (ie, ≤2 weeks after randomization) when patients were still receiving low-dose vericiguat identical to other study groups, thus suggesting the possibility of a chance finding.</s></p><p><s>The dose-response relationship of vericiguat with NT-proBNP level reduction in the prespecified exploratory secondary analyses warrants comment.</s><s>The 10-mg vericiguat group yielded concurrent improvements in NT-proBNP level and LVEF at 12 weeks, and the observed similarities in blood pressure and heart rate between the 10-mg vericiguat and placebo groups over this period suggest that these improvements were most likely not related to reduction in diastolic blood pressure.</s><s>In the setting of stable hemodynamics, these findings may signal intrinsic reverse remodeling of the heart with corresponding decreases in ventricular filling pressures and improvement in myocardial function.</s><s>7]<ref type="bibr" target="#b22">[18]</ref> In the current trial, although only exploratory in nature, the collective signal toward potential benefit in natriuretic peptide trajectory, clinical events, and LVEF at 12 weeks of treatment with the higher vericiguat dosing schedule, while maintaining safety, suggests that titration to the 5-mg or 10-mg once daily dose may be reasonable for further testing in a phase 3 study.</s></p><p><s>The contemporary treatment approach for HF with reduced LVEF centers on systemic blockade of the sympathetic and renin-angiotensin-aldosterone systems with hemodynamically active agents that decrease cardiac workload by reducing heart rate, preload, or afterload. <ref type="bibr" target="#b23">19</ref></s><s>These medications may lower blood pressure as an intended or unintended consequence.</s><s>Continued stepwise addition of investigational agents with pronounced blood pressure-lowering effects to target doses of existing guideline-directed medications raises safety and tolerability concerns. <ref type="bibr" target="#b23">19,</ref><ref type="bibr" target="#b24">20</ref></s><s>The present study generates the hypothesis that a once-daily sGC stimulator may exert favorable cardiac effects without sizeable changes in blood pressure and heart rate and thus may be safely tolerated for a broad HF population in combination with contemporary therapies.</s><s>Although the present study required systolic blood pressure 110 mm Hg or greater for enrollment, the observation that vericiguat, as titrated in SOCRATES-REDUCED, did not meaningfully influence mean blood pressure at 12 weeks' follow-up suggests this agent could be favorable for patients with worsening chronic HF who have even lower baseline blood pressure, a subpopulation at heightened risk of adverse outcomes yet less likely to tolerate available therapies proven to reduce morbidity and mortality. <ref type="bibr" target="#b25">21</ref></s><s>Independent of hemodynamic considerations, effective therapies for worsening chronic HF and reduced LVEF are needed, and SOCRATES-REDUCED is among the first studies to test a medication for this indication.</s></p><p><s>Limitations of the current study should be acknowledged.</s><s>Consistent with the dose-finding objective of this exploratory phase 2 trial, the findings from this study should be considered nonconfirmatory and descriptive, including the observed doseresponse relationship in the primary end point and reduction in NT-proBNP level in the 10-mg vericiguat target dose group compared with placebo.</s><s>By nature of its phase 2 design, SOCRATES-REDUCED was not intended to make definitive claims on the clinical efficacy of vericiguat in this study population.</s><s>Although change in natriuretic peptide level is a commonly used surrogate end point in HF studies due to associations with outcomes and response to proven guideline-therapies, discordance between natriuretic peptide improvement and clinical events may be seen with trials of investigational therapies. <ref type="bibr" target="#b26">22,</ref><ref type="bibr" target="#b28">23</ref></s><s>Moreover, although natriuretic peptide inclusion criteria differed in SOCRATES-REDUCED by presence or absence of atrial fibrillation, the effect of vericiguat on subsequent change in NT-proBNP level may have been influenced by the prevalence of atrial fibrillation in the population. <ref type="bibr" target="#b28">23</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Among patients with worsening chronic HF and reduced LVEF, compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well tolerated.</s><s>Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Flow of Patients Through the Trial</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Change From Baseline in NT-proBNP Level for Vericiguat Dose Groups Compared With Placebo (Per-Protocol Set)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3.</s><s>Time to Composite of Cardiovascular Death or Heart Failure Hospitalization</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Longitudinal Changes in Blood Pressure and Heart Rate</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Baseline Characteristics (Full Analysis Set)</s></p></div></figDesc><table><row><cell>632 Patients assessed for eligibility</cell></row></table><note><p><s>Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CRT-D, cardiac resynchronization therapy defibrillator; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.</s><s>a Calculated as weight in kilograms divided by height in meters squared.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Select Clinical Exploratory End Points (Full Analysis Set)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell>1.25 mg</cell><cell>2.5 mg</cell><cell>2.5 to 5 mg</cell><cell>2.5 to 10 mg</cell><cell></cell></row><row><cell>Clinical Outcome</cell><cell>(n = 92)</cell><cell>(n = 91)</cell><cell>(n = 91)</cell><cell>(n = 91)</cell><cell>(n = 91)</cell><cell></cell></row><row><cell>Up to week 12, No. (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All-cause death</cell><cell>3 (3.3)</cell><cell>4 (4.4)</cell><cell>3 (3.3)</cell><cell>3 (3.3)</cell><cell>2 (2.2)</cell><cell></cell></row><row><cell>CV death</cell><cell>3 (3.3)</cell><cell>4 (4.4)</cell><cell>2 (2.2)</cell><cell>2 (2.2)</cell><cell>2 (2.2)</cell><cell></cell></row><row><cell>HF hospitalization</cell><cell>16 (17.4)</cell><cell>16 (17.6)</cell><cell>16 (17.6)</cell><cell>9 (9.9)</cell><cell>9 (9.9)</cell><cell></cell></row><row><cell>CV death or HF hospitalization</cell><cell>18 (19.6)</cell><cell>17 (18.7)</cell><cell>18 (19.8)</cell><cell>11 (12.1)</cell><cell>10 (11.0)</cell><cell></cell></row><row><cell>End of follow-up (16 wk), No. (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All-cause death</cell><cell>6 (6.5)</cell><cell>6 (6.6)</cell><cell>5 (5.5)</cell><cell>3 (3.3)</cell><cell>4 (4.4)</cell><cell></cell></row><row><cell>CV death</cell><cell>6 (6.5)</cell><cell>5 (5.5)</cell><cell>4 (4.4)</cell><cell>2 (2.2)</cell><cell>4 (4.4)</cell><cell>Abbreviations: CV, cardiovascular; HF, heart failure.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Primary and Secondary Analyses of the Primary End Point (Change From Baseline to 12 Weeks in Log-Transformed NT-proBNP Level) (Per-Protocol Set)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Ratio of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Geometric Means</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Dosing Group</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Difference of Means</cell><cell>Change From Baseline/</cell><cell></cell></row><row><cell></cell><cell>Baseline</cell><cell>12-Week</cell><cell>Change From Baseline</cell><cell>(Dosing Group −</cell><cell>Placebo Group</cell><cell></cell></row><row><cell></cell><cell>NT-proBNP Level</cell><cell>NT-proBNP Level</cell><cell>(Ratio of Geometric</cell><cell>Placebo,</cell><cell>Change From Baseline,</cell><cell></cell></row><row><cell></cell><cell>(Log-Transformed</cell><cell>(Log-Transformed</cell><cell>Means 12-wk/Baseline,</cell><cell>Log-Transformed),</cell><cell>Back-Transformed)</cell><cell></cell></row><row><cell>Group</cell><cell>[SD])</cell><cell>[SD])</cell><cell>Back-Transformed)</cell><cell>90% CI</cell><cell>(90% CI)</cell><cell>P Value a</cell></row><row><cell cols="2">Primary Analysis of Primary End Point</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pooled treatment</cell><cell>7.969 (0.989)</cell><cell>7.567 (1.275)</cell><cell></cell><cell cols="2">−0.122 (−0.32 to 0.07) 0.885 (0.73 to 1.08)</cell><cell>.15</cell></row><row><cell>groups (2.5/5/10-mg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>vericiguat)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Geometric mean,</cell><cell>2890</cell><cell>1932</cell><cell>0.669</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>8.283 (0.983)</cell><cell>8.002 (1.029)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Geometric mean,</cell><cell>3955</cell><cell>2988</cell><cell>0.755</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Secondary Analysis of Primary End Point</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5-to 10-mg</cell><cell>8.131 (1.061)</cell><cell>7.602 (1.534)</cell><cell></cell><cell cols="2">−0.250 (−0.50 to 0.00) 0.779 (0.61 to 1.00)</cell><cell>.048</cell></row><row><cell>vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Geometric mean,</cell><cell>3400</cell><cell>2001</cell><cell>0.589</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5-to 5-mg vericiguat</cell><cell>7.761 (0.804)</cell><cell>7.407 (1.156)</cell><cell></cell><cell cols="2">−0.073 (−0.31 to 0.16) 0.930 (0.73 to 1.18)</cell><cell>.30</cell></row><row><cell>Geometric mean,</cell><cell>2346</cell><cell>1647</cell><cell>0.702</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5-mg vericiguat</cell><cell>7.998 (1.046)</cell><cell>7.678 (1.081)</cell><cell></cell><cell cols="2">−0.040 (−0.26 to 0.18) 0.961 (0.77 to 1.20)</cell><cell>.38</cell></row><row><cell>Geometric mean,</cell><cell>2976</cell><cell>2160</cell><cell>0.726</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1.25-mg vericiguat</cell><cell>7.962 (1.188)</cell><cell>7.696 (1.338)</cell><cell></cell><cell cols="2">0.015 (−0.21 to 0.24) 1.015 (0.81 to 1.27)</cell><cell>.54</cell></row><row><cell>Geometric mean,</cell><cell>2869</cell><cell>2201</cell><cell>0.767</cell><cell></cell><cell></cell><cell></cell></row><row><cell>back-transformed,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pg/mL</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Secondary Analysis of Primary End Point (Linear Regression Model to Assess Dose-Response Relationship of Study Drug)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Intercept</cell><cell>Slope</cell><cell>P Value b</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>−0.252</cell><cell>−0.026</cell><cell>.02</cell></row></table><note><p><s>Abbreviation: NT-proBNP, N-terminal pro-B-type natriuretic peptide.a</s><s>One-sided test.b</s><s>For decreasing slope.</s><s>P = .048).</s><s>Comparison of the primary end point between other individual vericiguat groups and placebo all yielded P &gt; .05 in these descriptive analyses.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Select Echocardiographic and Vital Sign Exploratory End Points</s></p></div></figDesc><table><row><cell></cell><cell>Change From Baseline</cell><cell>Difference of Means,</cell><cell>P Value</cell><cell></cell></row><row><cell></cell><cell>to 12 Weeks</cell><cell>Dosing Group − Placebo (95% CI)</cell><cell>(2-Sided)</cell><cell></cell></row><row><cell cols="2">Echocardiographic End Points, Full Analysis Set</cell><cell></cell><cell></cell><cell></cell></row><row><cell>LVEF, %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>1.52</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>3.68</cell><cell>2.17 (0.33 to 4.00)</cell><cell>.02</cell><cell></cell></row><row><cell>2.5 to 5 mg</cell><cell>2.07</cell><cell>0.56 (−1.08 to 2.19)</cell><cell>.50</cell><cell></cell></row><row><cell>2.5 mg</cell><cell>2.74</cell><cell>1.23 (−0.30 to 2.76)</cell><cell>.12</cell><cell></cell></row><row><cell>1.25 mg</cell><cell>2.84</cell><cell>1.33 (−0.12 to 2.77)</cell><cell>.07</cell><cell></cell></row><row><cell>LVEDV, mL</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>−7.26</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>−7.32</cell><cell>−0.07 (−12.28 to 12.15)</cell><cell>.99</cell><cell></cell></row><row><cell>2.5 to 5 mg</cell><cell>−17.09</cell><cell>−9.83 (−26.01 to 6.34)</cell><cell>.23</cell><cell></cell></row><row><cell>2.5 mg</cell><cell>−9.63</cell><cell>−2.37 (−15.12 to 10.37)</cell><cell>.71</cell><cell></cell></row><row><cell>1.25 mg</cell><cell>−5.53</cell><cell>1.73 (−11.19 to 14.66)</cell><cell>.79</cell><cell></cell></row><row><cell>LVESV, mL</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>−6.83</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>−11.02</cell><cell>−4.19 (−14.04 to 5.67)</cell><cell>.40</cell><cell></cell></row><row><cell>2.5 to 5 mg</cell><cell>−15.49</cell><cell>−8.66 (−21.67 to 4.36)</cell><cell>.19</cell><cell></cell></row><row><cell>2.5 mg</cell><cell>−10.94</cell><cell>−4.11 (−14.14 to 5.93)</cell><cell>.42</cell><cell></cell></row><row><cell>1.25 mg</cell><cell>−8.59</cell><cell>−1.76 (−12.01 to 8.50)</cell><cell>.74</cell><cell></cell></row><row><cell cols="2">Vital Sign End Points, Safety Analysis Set</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Systolic BP, mm Hg</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>−5.14</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>−5.64</cell><cell>−0.50 (−5.14 to 4.15)</cell><cell>.83</cell><cell></cell></row><row><cell>2.5 to 5 mg</cell><cell>−3.04</cell><cell>2.10 (−2.69 to 6.89)</cell><cell>.39</cell><cell></cell></row><row><cell>2.5 mg</cell><cell>−3.73</cell><cell>1.41 (−3.40 to 6.22)</cell><cell>.56</cell><cell></cell></row><row><cell>1.25 mg</cell><cell>−4.03</cell><cell>1.11 (−3.21 to 5.43)</cell><cell>.61</cell><cell></cell></row><row><cell>Diastolic BP, mm Hg</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>−4.17</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>−4.05</cell><cell>0.13 (−3.02 to 3.28)</cell><cell>.94</cell><cell></cell></row><row><cell>2.5 to 5 mg</cell><cell>−1.34</cell><cell>2.84 (−0.17 to 5.84)</cell><cell>.07</cell><cell></cell></row><row><cell>2.5 mg</cell><cell>−2.94</cell><cell>1.24 (−2.00 to 4.47)</cell><cell>.45</cell><cell></cell></row><row><cell>1.25 mg</cell><cell>−0.49</cell><cell>3.69 (0.73 to 6.65)</cell><cell>.02</cell><cell></cell></row><row><cell>Heart rate, /min</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>−0.56</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5 to 10 mg</cell><cell>0.55</cell><cell>1.11 (−2.74 to 4.96)</cell><cell>.57</cell><cell>Abbreviations: BP, blood pressure;</cell></row><row><cell>2.5 to 5 mg</cell><cell>−0.99</cell><cell>−0.43 (−4.46 to 3.60)</cell><cell>.83</cell><cell>LVEDV, left ventricular end-diastolic</cell></row><row><cell>2.5 mg</cell><cell>−1.56</cell><cell>−0.99 (−4.77 to 2.78)</cell><cell>.60</cell><cell>volume; LVEF, left ventricular</cell></row><row><cell>1.25 mg</cell><cell>−0.35</cell><cell>0.21 (−3.64 to 4.06)</cell><cell>.91</cell><cell>ejection fraction; LVESV, left ventricular end-systolic volume.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Adverse Events (Safety Analysis Set)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">No. of Patients (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Vericiguat</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell>1.25 mg</cell><cell>2.5 mg</cell><cell>2.5 to 5 mg</cell><cell>2.5 to 10 mg</cell><cell></cell></row><row><cell></cell><cell>(n = 92)</cell><cell>(n = 91)</cell><cell>(n = 90)</cell><cell>(n = 91)</cell><cell>(n = 91)</cell><cell></cell></row><row><cell>Any AE</cell><cell>71 (77.2)</cell><cell>64 (70.3)</cell><cell>71 (78.9)</cell><cell>67 (73.6)</cell><cell>65 (71.4)</cell><cell></cell></row><row><cell>Any study drug-related AE</cell><cell>13 (14.1)</cell><cell>10 (11.0)</cell><cell>13 (14.4)</cell><cell>12 (13.2)</cell><cell>15 (16.5)</cell><cell></cell></row><row><cell>AE with outcome death</cell><cell>5 (5.4)</cell><cell>6 (6.6)</cell><cell>4 (4.4)</cell><cell>2 (2.2)</cell><cell>4 (4.4)</cell><cell></cell></row><row><cell>Any SAE</cell><cell>36 (39.1)</cell><cell>31 (34.1)</cell><cell>35 (38.9)</cell><cell>24 (26.4)</cell><cell>29 (31.9)</cell><cell></cell></row><row><cell>Any study drug-related SAE</cell><cell>3 (3.3)</cell><cell>1 (1.1)</cell><cell>1 (1.1)</cell><cell>1 (1.1)</cell><cell>4 (4.4)</cell><cell></cell></row><row><cell>Discontinuation of study drug due to AE</cell><cell>7 (7.6)</cell><cell>10 (11.0)</cell><cell>9 (10.0)</cell><cell>8 (8.8)</cell><cell>8 (8.8)</cell><cell></cell></row><row><cell>Discontinuation of study drug due to SAE</cell><cell>5 (5.4)</cell><cell>6 (6.6)</cell><cell>2 (2.2)</cell><cell>5 (5.5)</cell><cell>7 (7.7)</cell><cell></cell></row><row><cell>Treatment-emergent AEs of interest</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hypotension a,b</cell><cell>6 (6.5)</cell><cell>5 (5.5)</cell><cell>6 (6.7)</cell><cell>4 (4.4)</cell><cell>14 (15.4) b</cell><cell>Abbreviations: AE, adverse event;</cell></row><row><cell>Asymptomatic</cell><cell>1 (1.1)</cell><cell>2 (2.2)</cell><cell>3 (3.3)</cell><cell>2 (2.2)</cell><cell>5 (5.5)</cell><cell>SAE, serious adverse event.</cell></row><row><cell>Symptomatic</cell><cell>5 (5.4)</cell><cell>3 (3.3)</cell><cell>3 (3.3)</cell><cell>2 (2.2)</cell><cell>10 (11.0)</cell><cell>a One patient had preferred term</cell></row><row><cell>Syncope</cell><cell>1 (1.1)</cell><cell>0</cell><cell>2 (2.2)</cell><cell>1 (1.1)</cell><cell>4 (4.4)</cell><cell>"orthostatic hypotension" reported.</cell></row><row><cell>Acute kidney injury</cell><cell>3 (3.3)</cell><cell>5 (5.5)</cell><cell>2 (2.2)</cell><cell>1 (1.1)</cell><cell>3 (3.3)</cell><cell></cell></row></table><note><p><s>bOne patient had both symptomatic and asymptomatic hypotension.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JAMA December 1, 2015 Volume 314, Number 21 (Reprinted) jama.com Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Role of the Funder/Sponsor: The sponsor participated in the design, conduct, and management of the study; the collection and analysis of the data; and the preparation, review, and approval of this manuscript.</s><s>The sponsor had no role in the interpretation of the data.</s><s>The sponsor did not have the right to prevent submission or publication of the data.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Heart failure-associated hospitalizations in the United States</title>
		<author>
			<persName><forename type="first">S</forename><surname>Blecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Taksler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ogedegbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1259" to="1267" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Acute heart failure syndromes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Pang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="557" to="573" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Dharmarajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="355" to="363" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Krumholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Normand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="966" to="975" />
			<date type="published" when="1999">1999-2011. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT</title>
		<author>
			<persName><forename type="first">H</forename><surname>Skali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Dwyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="560" to="565" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Marti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Sabbah</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Academic Research Team in Heart Failure (ART-HF)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Soluble guanylate cyclase: a potential therapeutic target for heart failure</title>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Rev</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="123" to="134" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Kass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="216" to="238" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Borlaug</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e000536</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Endothelial dysfunction, arterial stiffness, and heart failure</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Marti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kalogeropoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>Georgiopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Quyyumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Butler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1455" to="1469" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Mckie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schirger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Costello-Boerrigter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2095" to="2103" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pieske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1026" to="1038" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bonderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Felix</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="502" to="511" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ziesche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yancy</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure</title>
		<author>
			<persName><surname>African-American</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2049" to="2057" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Packer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Desai</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m">PARADIGM-HF Investigators and Committees</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Angiotensin-neprilysin inhibition versus enalapril in heart failure</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="993" to="1004" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Nitrate therapy for heart failure: benefits and strategies to overcome tolerance</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>Georgiopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kalogeropoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="183" to="191" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sharkovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kalk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lawrenz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1666" to="1675" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage</title>
		<author>
			<persName><forename type="first">K</forename><surname>Benz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Orth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Simonaviciene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Blood Press Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="224" to="233" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats</title>
		<author>
			<persName><forename type="first">H</forename><surname>Masuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuruda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="972" to="978" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Contemporary drug development in heart failure: call for hemodynamically neutral therapies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vaduganathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Heart Fail</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="826" to="831" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Heart Fail</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="918" to="925" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Ambrosy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vaduganathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mentz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="216" to="225" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Gheorghiade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Greene</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial</title>
	</analytic>
	<monogr>
		<title level="m">ASTRONAUT Investigators and Coordinators</title>
				<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="page" from="1125" to="1135" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Fonarow</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial</title>
	</analytic>
	<monogr>
		<title level="m">ASTRONAUT Investigators and Coordinators</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="98" to="108" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
